Research Compendium/CJC-1295
Growth Hormone AxisResearch OnlyNot For Human Consumption

CJC-1295

DAC:GRF · Drug Affinity Complex: Growth Hormone Releasing Factor

Long-acting GHRH analogue with albumin-binding DAC technology - extends GH pulse stimulation to 6–8 days per injection.

MECHANISM OF ACTION

CJC-1295 (with DAC) is a GHRH analogue engineered with a drug affinity complex (DAC) - a maleimidoproprionic acid conjugate that covalently binds albumin in vivo, extending half-life from ~30 min to ~6–8 days. Stimulates pituitary somatotrophs to secrete GH in a pulsatile manner, with 2–10× basal GH elevation and proportional IGF-1 increases. Preserves pituitary feedback regulation unlike exogenous GH.

RESEARCH APPLICATIONS

  • GH secretagogue research and pituitary axis modelling
  • Body composition - lean mass accretion and adipose reduction
  • IGF-1 axis stimulation research
  • Age-related GH decline (somatopause) models
  • Synergistic stacks with GHRP agents (Ipamorelin)

RESEARCH HIGHLIGHTS

Extended GH and IGF-1 Elevation

2006

Phase I/II trial showed single SC dose (2 mcg/kg) produced GH peak elevation lasting >6 days with proportional IGF-1 increases.

Ref: Teichman et al., JCEM

Sustained IGF-1 Response

2009

Twice-weekly administration maintained IGF-1 elevation above baseline for 14+ days with no tachyphylaxis over 6-week study periods.

Ref: Ionescu et al., Growth Horm IGF Res

RESEARCH PROTOCOL NOTES

Research doses1–2 mcg/kg or 500mcg–2mg fixed dose
CombinationStacked with Ipamorelin (GHRP) for synergistic GH pulse amplification - Growth Matrix Stack
Available formatsVial (2mg), Pen, self-mix kits (with Ipamorelin)

Chemical Identity

Molecular FormulaC165H269N47O46
Molecular Weight3647.1 g/mol
CAS Number863288-34-0
Half-Life (t½)6–8 days (with DAC); ~30 min without
SolubilitySoluble in bacteriostatic water

Storage & Stability

Lyophilised: 2–8°C or -20°C. Reconstituted: 2–8°C, 21–28 days. Avoid room temperature.

Regulatory Status

No regulatory approval. WADA prohibited (S2). SAHPRA: import authorisation required for research.

Back to Research CompendiumView Research Compounds →